Second and third line treatment in non-small cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference69 articles.
1. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (7th) edition of the TNM classification of malignant tumours;Goldstraw;J Thorac Oncol,2007
2. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000
3. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced NSCLC previously treated with platinum-containing regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group;Fossella;J Clin Oncol,2000
4. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004
5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer;European Journal of Pharmacology;2020-12
2. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC;International Journal of Clinical Oncology;2019-03-04
3. Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer;Asian Pacific Journal of Cancer Prevention;2014-08-30
4. Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer;Thoracic Cancer;2014-03
5. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis;Journal of Cancer Research and Clinical Oncology;2012-01-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3